Modulation of tissue factor and tissue factor pathway inhibitor-1 by neutrophil proteases

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH08-05-0293
Issue:2008: 100/6 (Dec) pp. 955-1217
Pages:1068-1075

Modulation of tissue factor and tissue factor pathway inhibitor-1 by neutrophil proteases

Birgit A. Steppich; Isabell Seitz; Gabi Busch; Andreas Stein; Ilka Ott
Deutsches Herzzentrum der Technischen Universität München, Munich, Germany

Summary

During systemic inflammation, neutrophil activation is accompanied by endothelial cell damage and hypercoagulability. Activated neutrophils release serine proteases that participate in tissue injury.We sought to investigate the effects of neutrophil proteases on proinflammatory and procoagulant changes in endothelial cells.The effects of elastase (HNE), cathepsin G (CG), and proteinase 3 (PR3) on expression of tissue factor (TF) and tissue factor pathway inhibitor-1 (TFPI) were examined in human umbilical vein endothelial cells. Flow cytometry demonstrated that these proteases proteolytically degraded endothelial cell-bound TFPI. TFPI mRNA expression was reduced by HNE and CG. PR3, but not HNE or CG, increased surface expression of TF and TF mRNA.Yet, increased TF expression did not enhance TF activity suggesting induction of encrypted TF. Using antibodies and siRNA to inhibit and silence PAR-1 and PAR-2, we observed that PR3 upregulation of TF is at least in part mediated by PAR-1.Although CG and HNE cleaved PAR-1, antibody reactivity to the PAR-1 hirudin-like sequence demonstrated inactivating cleavage, accounting for the selective ability of PR3 to induce PAR-1-mediated procoagulant effects.This was supported by induction of p42/44 MAPK by PR3. In conclusion, PR3 degradation of TFPI increases the procoagulant activity of endothelial cells. Release of PR3 after neutrophil activation may represent an important step in neutrophil-mediated vascular injury.

Keywords

proteinase 3, Tissue factor (TF), cathepsin G, tissue factor pathway inhibitor (TFPI), human neutrophil elastase

DOI

http://dx.doi.org/10.1160/TH08-05-0293

You may also be interested in...

1.

Andrew J. Gale, Diana Rozenshteyn

Thrombosis and Haemostasis 2008 99 1: 44-51

http://dx.doi.org/10.1160/TH07-08-0495

2.

Jihwa Chung1, Hidenori Suzuki2, Noriyuki Tabuchi3, Kengo Sato1, Aya Shibamiya1, Takatoshi Koyama1

Thrombosis and Haemostasis 2007 98 2: 368-375

http://dx.doi.org/10.1160/TH07-01-0025

3.

Konstantinos Konstantinidis1, Thomas Gerasimidis1, Elisabeth Verdy2,3, Ismail Elalamy2,3, Michel M. Samama3,4, Grigoris T. Gerotziafas2,3

Thrombosis and Haemostasis 2007 97 1: 109-118

http://dx.doi.org/10.1160/TH05-10-0701



Articles

You've 533 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...